BELCO-PHARM
0726.954.721 · rovalta.com · 22/09/2026
BELCO-PHARM
Company — Normal situation.
Overview
What does BELCO-PHARM do?
BELCO-PHARM is a company registered in Belgium.
Trend over 6 financial years
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Gross margin | -1,5 k € | +60.7% | -3,8 k € | -56.5% | -2,4 k € | -117% | 14,1 k € | +189% | -15,9 k € | +3.7% | -16,5 k € |
| EBITDA | -1,5 k € | +60.7% | -3,8 k € | -56.5% | -2,4 k € | +98.5% | -159,1 k € | -901% | -15,9 k € | +3.7% | -16,5 k € |
| Operating result | -7,8 k € | -106% | -3,8 k € | -56.5% | -2,4 k € | +98.5% | -159,1 k € | -901% | -15,9 k € | +3.7% | -16,5 k € |
| Net result | 13,3 k € | +450% | -3,8 k € | -55.9% | -2,4 k € | +98.7% | -182,9 k € | -429% | -34,6 k € | -12.9% | -30,6 k € |
| Balance sheet | |||||||||||
| Equity | 359 k € | +3.9% | 345,6 k € | -1.1% | 349,5 k € | -0.7% | 351,9 k € | -34.2% | 534,8 k € | -6.1% | 569,4 k € |
| Total assets | 359,2 k € | +3.9% | 345,6 k € | -1.1% | 349,5 k € | -47.8% | 669,4 k € | -73.6% | 2,5 M € | +0.0% | 2,5 M € |
| Cash | 352,9 € | +30.8% | 269,9 € | -99.4% | 44 k € | +1345% | 3 k € | +215% | 967,5 € | +359% | 210,7 € |
| Debts | 37,3 € | – | – | 317,5 k € | -84.1% | 2 M € | +1.8% | 2 M € | |||
Board of directors
Seen on filing of 31/12/2024 · 2 active
Active mandates
Financials
Full financial information
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|
| Type of account | Micro model | Micro model | Micro model | Micro model | Micro model | Micro model |
| Start of the financial year | 01/01/2024 | 01/01/2023 | 01/01/2022 | 01/01/2021 | 01/01/2020 | 01/01/2019 |
| Closing of the financial year | 31/12/2024 | 31/12/2023 | 31/12/2022 | 31/12/2021 | 31/12/2020 | 31/12/2019 |
| Length of the financial year | 12 months | 12 months | 12 months | 12 months | 12 months | 12 months |
| Filing date | 18/07/2025 | 26/06/2024 | 29/06/2023 | 21/06/2022 | 26/08/2021 | 18/08/2020 |
| General meeting | 02/06/2025 | 03/06/2024 | 05/06/2023 | 07/06/2022 | 07/06/2021 | 02/06/2020 |
| Currency of the financial year | EUR | EUR | EUR | EUR | EUR | EUR |
| NBB quality label | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls | Satisfying controls |
Financial ratios
Looking for more information about this company?
Try for 7 daysAnnual accounts filings
6 filings with the NBB
| Model | Closing | General meeting | Filed | Language | Document |
|---|---|---|---|---|---|
| Micro model | 31/12/2024 | 02/06/2025 | 18/07/2025 | French | |
| Micro model | 31/12/2023 | 03/06/2024 | 26/06/2024 | French | |
| Micro model | 31/12/2022 | 05/06/2023 | 29/06/2023 | French | |
| Micro model | 31/12/2021 | 07/06/2022 | 21/06/2022 | French | |
| Micro model | 31/12/2020 | 07/06/2021 | 26/08/2021 | French | |
| Micro model | 31/12/2019 | 02/06/2020 | 18/08/2020 | French |
Valuation
Indicative valuation
The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.
Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.
Directors & structure
Board of directors
Seen on filing of 31/12/2024 · 2 active
Active mandates
Ownership and network
Looking for more information about this company?
Try for 7 daysPublications
Similar companies
Similar companies
A company's peers, by sector and size, are included in the Business plan.
See the Business planTimeline
Timeline
- 2024Annual accounts 202413,3 k €↑
- 2023Annual accounts 2023-3,8 k €↓
- 2022Annual accounts 2022-2,4 k €↑
- 2021Annual accounts 2021-182,9 k €↓
- 2020Annual accounts 2020-34,6 k €↓
- 2019Annual accounts 2019-30,6 k €